Cargando…
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
Migraine is a prevalent disorder and a cause of high disability, influenced by modifiable and non-modifiable risk factors. Comorbid and psychiatric illnesses are prevalent in migraine patients and should be considered when choosing preventive drugs. There have been unforeseen problems with the use o...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academia Brasileira de Neurologia - ABNEURO
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491416/ https://www.ncbi.nlm.nih.gov/pubmed/35976315 http://dx.doi.org/10.1590/0004-282X-ANP-2022-S125 |